{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000041","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.874476+00:00","generated_at":"2026-06-03T00:53:54.427720+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Senti Biosciences appoints Yvonne Li Interim CFO; CEO Lu named interim PFO","bullets":["Timothy Lu, CEO/President, becomes interim principal financial & accounting officer effective May 4, 2024.","Yvonne Li appointed Interim CFO effective May 4, 2024; will become principal financial & accounting officer after Q1 10-Q filing.","Li consulting agreement: $350/hour, max aggregate payment of $370,000."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000041","json":"https://secwatch.observer/filing/0001854270-24-000041.json","markdown":"https://secwatch.observer/filing/0001854270-24-000041.md","text":"https://secwatch.observer/filing/0001854270-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/0001854270-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/snti-20240426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:53:54.427720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97a9060c68","claim":"Yvonne Li was appointed as Interim Chief Financial Officer at Senti Biosciences, Inc..","evidence_excerpt":"Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/0001854270-24-000041-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}]},{"claim_id":"c1ad96b877","claim":"Timothy Lu was appointed as interim principal financial officer and principal accounting officer at Senti Biosciences, Inc..","evidence_excerpt":"Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/0001854270-24-000041-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer and principal accounting officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}